See more : Tevogen Bio Holdings Inc. (TVGN) Income Statement Analysis – Financial Results
Complete financial analysis of DaVita Inc. (DVA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DaVita Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Maestros Electronics & Telecommunications Systems Limited (METSL.BO) Income Statement Analysis – Financial Results
- Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) Income Statement Analysis – Financial Results
- Microbio Co., Ltd. (4128.TWO) Income Statement Analysis – Financial Results
- Vaisala Oyj (VAIAF) Income Statement Analysis – Financial Results
- Silex Systems Limited (SILXF) Income Statement Analysis – Financial Results
DaVita Inc. (DVA)
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.14B | 11.61B | 11.62B | 11.55B | 11.39B | 11.40B | 10.88B | 14.75B | 13.78B | 12.80B | 11.76B | 8.19B | 6.79B | 6.45B | 6.11B | 5.66B | 5.26B | 4.88B | 2.97B | 2.30B | 2.05B | 1.85B | 1.65B | 1.49B | 1.45B | 1.20B | 438.20M | 272.90M | 89.70M | 99.00M |
| Cost of Revenue | 8.32B | 8.21B | 7.97B | 7.99B | 7.91B | 8.20B | 7.64B | 10.65B | 9.82B | 9.12B | 8.20B | 5.58B | 4.68B | 4.47B | 4.25B | 3.92B | 3.59B | 3.39B | 2.04B | 1.56B | 1.36B | 1.22B | 1.10B | 1.03B | 993.24M | 772.70M | 292.50M | 184.00M | 57.40M | 65.60M |
| Gross Profit | 3.82B | 3.40B | 3.65B | 3.56B | 3.47B | 3.21B | 3.24B | 4.10B | 3.96B | 3.68B | 3.57B | 2.61B | 2.11B | 1.97B | 1.86B | 1.74B | 1.67B | 1.49B | 938.68M | 743.53M | 685.86M | 636.95M | 550.10M | 454.15M | 452.11M | 432.20M | 145.70M | 88.90M | 32.30M | 33.40M |
| Gross Profit Ratio | 31.47% | 29.29% | 31.38% | 30.84% | 30.50% | 28.14% | 29.76% | 27.79% | 28.71% | 28.73% | 30.31% | 31.85% | 31.08% | 30.60% | 30.45% | 30.74% | 31.80% | 30.54% | 31.56% | 32.35% | 33.52% | 34.34% | 33.32% | 30.56% | 31.28% | 35.87% | 33.25% | 32.58% | 36.01% | 33.74% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.47B | 1.36B | 1.20B | 1.25B | 1.10B | 1.14B | 1.06B | 1.59B | 1.45B | 1.26B | 1.18B | 894.58M | 691.24M | 579.00M | 531.53M | 654.47M | 627.92M | 579.72M | 334.38M | 233.04M | 195.33M | 181.33M | 126.90M | 163.27M | 263.81M | 120.20M | 38.70M | 24.80M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.47B | 1.36B | 1.20B | 1.25B | 1.10B | 1.14B | 1.06B | 1.59B | 1.45B | 1.26B | 1.18B | 894.58M | 691.24M | 579.00M | 531.53M | 654.47M | 627.92M | 579.72M | 334.38M | 233.04M | 195.33M | 181.33M | 126.90M | 163.27M | 263.81M | 120.20M | 38.70M | 24.80M | 9.40M | 11.50M |
| Other Expenses | 743.66M | 732.60M | 680.62M | 630.44M | 615.15M | 583.74M | 17.67M | 8.73M | 8.89M | 2.37M | 4.79M | 3.74M | 455.42M | 396.63M | 388.33M | 263.45M | 183.68M | 171.16M | 138.93M | 100.36M | 112.00M | 64.29M | 105.21M | 111.61M | 112.48M | 92.00M | 27.10M | 15.40M | 4.40M | 0.00 |
| Operating Expenses | 2.22B | 2.09B | 1.88B | 1.88B | 1.72B | 1.72B | 1.62B | 2.32B | 2.59B | 1.88B | 2.11B | 1.33B | 956.43M | 975.63M | 919.86M | 917.92M | 811.60M | 750.88M | 473.30M | 333.40M | 307.33M | 245.62M | 232.11M | 274.88M | 376.29M | 212.20M | 65.80M | 40.20M | 13.80M | 16.20M |
| Cost & Expenses | 10.54B | 10.30B | 9.85B | 9.87B | 9.63B | 9.91B | 9.26B | 12.97B | 12.42B | 11.00B | 10.31B | 6.91B | 5.64B | 5.45B | 5.17B | 4.84B | 4.40B | 4.14B | 2.51B | 1.89B | 1.67B | 1.46B | 1.33B | 1.31B | 1.37B | 984.90M | 358.30M | 224.20M | 71.20M | 81.80M |
| Interest Income | 0.00 | 368.75M | 279.75M | 297.03M | 435.23M | 0.00 | 0.00 | 0.00 | 0.00 | 17.41M | 0.00 | 288.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 398.55M | 357.02M | 285.25M | 304.11M | 443.82M | 487.44M | 430.63M | 414.38M | 405.94M | 410.29M | 429.94M | 0.00 | 241.09M | 255.99M | 185.76M | 199.89M | 156.95M | 489.02M | 107.74M | 44.07M | 113.71M | 98.33M | 71.43M | 149.58M | 399.35M | 256.00M | 15.40M | 14.40M | 4.10M | 0.00 |
| Depreciation & Amortization | 745.44M | 732.60M | 680.62M | 630.44M | 615.15M | 591.04M | 559.91M | 509.50M | 638.02M | 590.94M | 528.12M | 343.91M | 267.32M | 234.38M | 228.99M | 216.92M | 193.47M | 173.30M | 119.72M | 86.67M | 74.69M | 64.67M | 105.21M | 111.61M | 112.48M | 92.00M | 27.10M | 15.40M | 4.40M | 4.70M |
| EBITDA | 2.35B | 2.05B | 2.45B | 2.31B | 2.37B | 2.08B | 2.38B | 2.55B | 1.77B | 2.43B | 2.10B | 1.63B | 1.43B | 1.23B | 1.16B | 1.03B | 1.06B | 912.73M | 465.37M | 467.79M | 434.62M | 448.49M | 416.07M | 290.88M | 188.30M | 303.40M | 165.20M | 105.70M | 33.20M | 21.90M |
| EBITDA Ratio | 19.33% | 17.71% | 21.38% | 20.42% | 21.19% | 18.30% | 22.12% | 17.06% | 14.37% | 18.06% | 17.23% | 19.96% | 20.94% | 19.10% | 19.14% | 18.13% | 18.58% | 23.33% | 19.50% | 21.43% | 23.29% | 24.25% | 25.36% | 20.36% | 22.83% | 31.98% | 23.87% | 22.79% | 24.75% | 22.12% |
| Operating Income | 1.60B | 1.34B | 1.80B | 1.69B | 1.64B | 1.53B | 1.81B | 1.89B | 1.17B | 1.82B | 1.55B | 1.30B | 1.13B | 997.03M | 940.27M | 821.77M | 862.21M | 739.43M | 465.37M | 410.12M | 378.54M | 391.33M | 317.99M | 179.27M | 75.82M | 220.00M | 79.90M | 48.70M | 18.50M | 17.20M |
| Operating Income Ratio | 13.20% | 11.53% | 15.47% | 14.67% | 14.43% | 13.38% | 16.67% | 12.85% | 8.49% | 14.19% | 13.18% | 15.84% | 16.65% | 15.46% | 15.39% | 14.52% | 16.38% | 15.15% | 15.65% | 17.84% | 18.50% | 21.10% | 19.26% | 12.06% | 5.25% | 18.26% | 18.23% | 17.85% | 20.62% | 17.37% |
| Total Other Income/Expenses | -425.69M | -372.78M | -278.88M | -376.37M | -447.88M | -477.35M | -412.97M | -406.61M | -413.63M | -505.47M | -425.16M | -295.78M | -238.11M | -252.57M | -182.05M | -164.97M | -234.69M | -263.67M | -134.27M | -19.24M | -71.67M | -67.64M | -68.29M | -134.34M | -257.65M | -164.40M | 1.30M | 8.70M | -3.60M | -8.80M |
| Income Before Tax | 1.18B | 966.28M | 1.52B | 1.32B | 1.20B | 1.05B | 1.40B | 1.49B | 723.14M | 1.31B | 1.12B | 1.00B | 892.67M | 744.46M | 758.22M | 609.46M | 627.52M | 475.76M | 331.10M | 361.88M | 288.27M | 316.19M | 240.94M | 44.94M | -181.83M | 56.90M | 62.10M | 40.10M | 11.10M | 8.40M |
| Income Before Tax Ratio | 9.70% | 8.32% | 13.07% | 11.41% | 10.50% | 9.19% | 12.87% | 10.10% | 5.25% | 10.24% | 9.56% | 12.23% | 13.14% | 11.55% | 12.41% | 10.77% | 11.92% | 9.75% | 11.13% | 15.74% | 14.09% | 17.05% | 14.60% | 3.02% | -12.58% | 4.72% | 14.17% | 14.69% | 12.37% | 8.48% |
| Income Tax Expense | 220.12M | 198.09M | 306.73M | 313.93M | 279.63M | 258.40M | 323.86M | 455.81M | 295.73M | 446.34M | 381.01M | 359.85M | 315.74M | 260.24M | 278.47M | 235.30M | 245.74M | 186.43M | 123.68M | 139.63M | 112.48M | 129.50M | 104.60M | 27.96M | -34.57M | 41.60M | 25.10M | 16.40M | 4.60M | 3.50M |
| Net Income | 691.54M | 768.19M | 978.45M | 773.64M | 810.98M | 790.08M | 663.62M | 879.87M | 269.73M | 723.11M | 633.45M | 536.02M | 478.00M | 405.68M | 422.68M | 374.16M | 381.78M | 289.69M | 228.64M | 222.25M | 175.79M | 157.33M | 137.32M | 13.49M | -147.26M | -4.30M | 37.00M | 16.00M | 9.10M | 4.90M |
| Net Income Ratio | 5.70% | 6.62% | 8.42% | 6.70% | 7.12% | 6.93% | 6.10% | 5.97% | 1.96% | 5.65% | 5.38% | 6.55% | 7.04% | 6.29% | 6.92% | 6.61% | 7.25% | 5.94% | 7.69% | 9.67% | 8.59% | 8.48% | 8.32% | 0.91% | -10.19% | -0.36% | 8.44% | 5.86% | 10.14% | 4.95% |
| EPS | 7.62 | 8.26 | 9.30 | 6.54 | 5.29 | 4.63 | 3.52 | 4.36 | 1.27 | 3.41 | 3.02 | 2.79 | 2.52 | 2.00 | 2.04 | 1.78 | 1.80 | 1.40 | 1.13 | 1.13 | 0.93 | 0.73 | 0.55 | 0.06 | -0.60 | -0.02 | 0.24 | 0.14 | 0.08 | 0.09 |
| EPS Diluted | 7.42 | 8.02 | 8.90 | 6.39 | 5.27 | 4.58 | 3.47 | 4.29 | 1.25 | 3.33 | 2.95 | 2.74 | 2.48 | 1.97 | 2.03 | 1.77 | 1.78 | 1.37 | 1.10 | 1.08 | 0.77 | 0.58 | 0.49 | 0.05 | -0.60 | -0.02 | 0.24 | 0.13 | 0.08 | 0.08 |
| Weighted Avg Shares Out | 90.79M | 92.99M | 105.23M | 119.80M | 153.18M | 170.79M | 188.63M | 201.64M | 211.87M | 212.30M | 209.94M | 192.04M | 189.32M | 203.01M | 207.21M | 210.30M | 211.79M | 207.04M | 201.52M | 197.45M | 188.69M | 215.49M | 251.30M | 244.74M | 243.46M | 240.43M | 155.05M | 114.73M | 111.48M | 54.42M |
| Weighted Avg Shares Out (Dil) | 93.18M | 95.83M | 109.95M | 122.62M | 153.81M | 172.36M | 191.35M | 204.90M | 216.25M | 216.93M | 214.76M | 195.94M | 193.06M | 206.12M | 208.34M | 211.88M | 214.84M | 211.59M | 208.14M | 205.72M | 227.52M | 271.44M | 278.82M | 249.47M | 243.46M | 245.10M | 155.05M | 119.94M | 111.48M | 61.22M |
DaVita Inc. 3rd Quarter 2024 Results
DENVER , Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third...
6 Stocks Dominate Market's 'Best 6 Months' — Starting This Week
If you had to choose the best time to invest in the S&P 500 — it's the six months starting in November.
DaVita Emphasizes Commitment to Whole-Person Care with Investment in National Kidney Foundation PEERS Program
The program aims to bring together a supportive network for people dealing with chronic health challenges for themselves and their loved ones DENVER , Oct. 28, 2024 /PRNewswire/ -- The DaVita Giving Foundation today announced an investment in the National Kidney...
DVA Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
Improvement in RPT is likely to have boosted DaVita's top line in the third quarter.
DaVita Research Centers on Upstream CKD Management; Access & Equity during ASN's Kidney Week 2024
DENVER and SAN DIEGO , Oct. 23, 2024 /PRNewswire/ -- DaVita Clinical Research (DCR), a leading innovator in kidney care research and wholly owned subsidiary of DaVita Inc., will present the results of five innovative research projects at the American...
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
DaVita HealthCare (DVA) concluded the recent trading session at $163.16, signifying a +1% move from its prior day's close.
DaVita celebrates kidney care community achievements in year one of largest-ever value-based care program
Nephrologists drive transformative outcomes through government's coordinated care program serving high-need patients DENVER , Oct. 22, 2024 /PRNewswire/ -- DaVita today announced performance year one clinical outcomes achieved in partnership with nearly 1,300 nephrologists across the U.S. through value-based care...
DaVita Appoints Jessica Hergenreter as Chief People Officer
DENVER , Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and...
DaVita HealthCare (DVA) Advances But Underperforms Market: Key Facts
In the most recent trading session, DaVita HealthCare (DVA) closed at $164.82, indicating a +0.15% shift from the previous trading day.
Can DaVita Stock Continue Its Bull Run After Doubling in a Year?
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
Source: https://incomestatements.info
Category: Stock Reports